| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
|
Arthritis Rheum
|
2012
|
6.85
|
|
2
|
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
|
Arthritis Rheum
|
2006
|
5.68
|
|
3
|
Tofacitinib versus methotrexate in rheumatoid arthritis.
|
N Engl J Med
|
2014
|
4.64
|
|
4
|
Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study.
|
Arthritis Rheum
|
2013
|
4.02
|
|
5
|
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
|
Arthritis Rheum
|
2011
|
3.81
|
|
6
|
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?
|
Arthritis Rheum
|
2009
|
2.97
|
|
7
|
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists.
|
Ann Rheum Dis
|
2007
|
2.53
|
|
8
|
Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
|
Arthritis Rheum
|
2013
|
2.25
|
|
9
|
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.
|
Ann Rheum Dis
|
2012
|
2.21
|
|
10
|
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.
|
Ann Rheum Dis
|
2011
|
1.93
|
|
11
|
Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
|
Arthritis Rheum
|
2007
|
1.87
|
|
12
|
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
|
Ann Rheum Dis
|
2011
|
1.68
|
|
13
|
Patterns of interaction between genetic and nongenetic attributes and methotrexate efficacy in rheumatoid arthritis.
|
Pharmacogenet Genomics
|
2012
|
1.65
|
|
14
|
Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial.
|
JAMA Intern Med
|
2013
|
1.60
|
|
15
|
Integrated safety in tocilizumab clinical trials.
|
Arthritis Res Ther
|
2011
|
1.55
|
|
16
|
Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis.
|
Arthritis Rheum
|
2009
|
1.49
|
|
17
|
Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial.
|
Ann Rheum Dis
|
2010
|
1.42
|
|
18
|
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study.
|
Rheumatology (Oxford)
|
2012
|
1.31
|
|
19
|
In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial.
|
Ann Rheum Dis
|
2011
|
1.21
|
|
20
|
Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial.
|
Ann Rheum Dis
|
2011
|
1.17
|
|
21
|
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration.
|
Ann Rheum Dis
|
2011
|
1.14
|
|
22
|
Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.
|
Ann Rheum Dis
|
2011
|
1.12
|
|
23
|
Skewed distribution of proinflammatory CD4+CD28null T cells in rheumatoid arthritis.
|
Arthritis Res Ther
|
2007
|
1.11
|
|
24
|
Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue.
|
Ann Rheum Dis
|
2007
|
1.05
|
|
25
|
Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study.
|
BMC Musculoskelet Disord
|
2013
|
1.03
|
|
26
|
Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study.
|
BMC Med
|
2012
|
1.03
|
|
27
|
Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study.
|
Ann Rheum Dis
|
2012
|
1.02
|
|
28
|
Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts.
|
Rheumatology (Oxford)
|
2010
|
1.02
|
|
29
|
Antibodies to citrullinated α-enolase peptide 1 and clinical and radiological outcomes in rheumatoid arthritis.
|
Ann Rheum Dis
|
2011
|
0.96
|
|
30
|
Case 16-2013: A girl with irritability, hypersomnia, and somatic symptoms.
|
N Engl J Med
|
2013
|
0.96
|
|
31
|
Treat-to-target in systemic lupus erythematosus: where are we today?
|
Clin Exp Rheumatol
|
2012
|
0.91
|
|
32
|
Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
|
Cochrane Database Syst Rev
|
2014
|
0.91
|
|
33
|
VH4-34 encoded antibody in systemic lupus erythematosus: effect of isotype.
|
J Rheumatol
|
2002
|
0.90
|
|
34
|
Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate.
|
Ann Rheum Dis
|
2012
|
0.89
|
|
35
|
Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.
|
Arthritis Rheum
|
2012
|
0.87
|
|
36
|
Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
|
Arthritis Rheum
|
2013
|
0.86
|
|
37
|
Ten years with biologics: to whom do data on effectiveness and safety apply?
|
Rheumatology (Oxford)
|
2010
|
0.85
|
|
38
|
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
|
Ann Rheum Dis
|
2012
|
0.85
|
|
39
|
Diagnostic utility of musculoskeletal ultrasound in patients with suspected arthritis--a probabilistic approach.
|
Arthritis Res Ther
|
2014
|
0.84
|
|
40
|
How to dose infliximab in rheumatoid arthritis: new data on a serious issue.
|
Ann Rheum Dis
|
2009
|
0.84
|
|
41
|
Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study.
|
Ann Rheum Dis
|
2012
|
0.82
|
|
42
|
Patient-reported 28 swollen and tender joint counts accurately represent RA disease activity and can be used to assess therapy responses at the group level.
|
Rheumatology (Oxford)
|
2010
|
0.82
|
|
43
|
B cell lymphoproliferative disorders and VH4-34 gene encoded antibodies.
|
Hum Antibodies
|
2004
|
0.82
|
|
44
|
Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense deposits.
|
Ann Rheum Dis
|
2011
|
0.81
|
|
45
|
Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden.
|
Int J Technol Assess Health Care
|
2010
|
0.80
|
|
46
|
Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study.
|
BMJ Open
|
2012
|
0.80
|
|
47
|
The treatment of rheumatoid arthritis: getting better all the time?
|
Arthritis Rheum
|
2005
|
0.79
|
|
48
|
Patient preference assessment reveals disease aspects not covered by recommended outcomes in polymyositis and dermatomyositis.
|
ISRN Rheumatol
|
2011
|
0.79
|
|
49
|
Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response.
|
Rheumatology (Oxford)
|
2013
|
0.78
|
|
50
|
Evaluation of hand bone loss by digital X-ray radiogrammetry as a complement to clinical and radiographic assessment in early rheumatoid arthritis: results from the SWEFOT trial.
|
BMC Musculoskelet Disord
|
2013
|
0.77
|
|
51
|
Biologicals for the treatment of systemic lupus erythematosus?
|
Ann Med
|
2011
|
0.77
|
|
52
|
Tofacitinib versus methotrexate in rheumatoid arthritis.
|
N Engl J Med
|
2014
|
0.77
|
|
53
|
The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice.
|
Eur J Health Econ
|
2012
|
0.77
|
|
54
|
Rituximab and lupus--a promising pair?
|
Curr Rheumatol Rep
|
2014
|
0.76
|
|
55
|
More or less rituximab? Biology and clinic, regulators and researchers.
|
Arthritis Rheum
|
2011
|
0.76
|
|
56
|
Rheumatologists, take heart! We may be doing something right.
|
Arthritis Res Ther
|
2008
|
0.75
|
|
57
|
Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Reply.
|
Arthritis Rheumatol
|
2014
|
0.75
|